[The role of perioperative chemotherapy in patients with resectable colorectal liver metastases].
Surgical resection remains the only treatment of colorectal liver metastases that can ensure long-term survival and cure in some patients, but only a minority of patients with liver metastases is directly amenable to surgery. Cancer relapse is observed in the majority of patients after resection of liver metastases despite progress in surgical technique and improved surgical skills. In order to decrease the risk of cancer relapse, it has been proposed to combine surgery and chemotherapy, which could be administered before, after or before and after surgery. It has been demonstrated that perioperative chemotherapy can reduce the risk of cancer relapse and should be considered as the standard of care for most patients with resectable colorectal liver metastases. However perioperative chemotherapy has also potential disadvantages. This review will summarize the current data on the rationale, benefits and potential disadvantages of perioperative chemotherapy in patients with resectable colorectal liver metastases.
Brouquet
A
A
Service de Chirurgie Digestive et Oncologique AP-HP, Hôpital Ambroise Paré, 9, avenue Charles-de-Gaulle, 92104 Boulogne cedex, France; Université de Versailles - Saint-Quentin-en-Yvelines, 23, rue du Refuge, 78000 Versailles, France.
Mitry
E
E
Benoist
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011379:Prognosis; D012004:Rectal Neoplasms / Q000473:pathology*; D012307:Risk Factors